← Back to Search

Insulin Injection Sites for Diabetes

N/A
Waitlist Available
Led By Graydon Meneilly, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 19 years of age
Diagnosed with Type 1 or Type 2 diabetes for at least 2 years
Must not have
Taking other injectable diabetes medications (i.e. liraglutide, Victoza)
Taking insulin secretagogues (gliclazide, glyburide, glipizide)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up continuously for 12 days
Awards & highlights
No Placebo-Only Group

Summary

This trialexamines if injecting insulin in areas of subclinical lipohypertrophy affects insulin absorption and glycemic control in people with diabetes.

Who is the study for?
This trial is for people over 19 who have had Type 1 or Type 2 diabetes for at least two years and are using insulin. They must have been part of phase 1 of the study and identified with subclinical lipohypertrophy. Those on certain diabetes medications, steroids, or unable to communicate in English without a translator cannot join.
What is being tested?
The study is looking into how well insulin is absorbed in areas affected by subclinical lipohypertrophy—a kind of localized swelling due to repeated injections. At least 20 participants will use continuous glucose monitoring to see if there's a link between their blood sugar control and the amount of insulin injected into these swollen spots.
What are the potential side effects?
Since this trial involves standard diabetes care practices, side effects may include those typically associated with insulin therapy such as low blood sugar levels, injection site reactions, and possible skin changes where injections are given.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 19 years old or older.
Select...
I have been diagnosed with diabetes for at least 2 years.
Select...
I use insulin to manage my diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking injectable diabetes medications.
Select...
I am taking medication to increase my body's insulin production.
Select...
I am currently taking steroids like prednisone.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~continuously for 12 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and continuously for 12 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood glucose levels

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Normal Subcutaneous TissueExperimental Treatment1 Intervention
Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
Group II: LipohypertrophyExperimental Treatment1 Intervention
Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,447 Total Patients Enrolled
10 Trials studying Diabetes
363 Patients Enrolled for Diabetes
MedtronicIndustry Sponsor
619 Previous Clinical Trials
764,079 Total Patients Enrolled
4 Trials studying Diabetes
164 Patients Enrolled for Diabetes
Graydon Meneilly, MDPrincipal InvestigatorUniversity of British Columbia
6 Previous Clinical Trials
165 Total Patients Enrolled
1 Trials studying Diabetes
100 Patients Enrolled for Diabetes

Media Library

Lipohypertrophy Clinical Trial Eligibility Overview. Trial Name: NCT02748434 — N/A
Diabetes Research Study Groups: Lipohypertrophy, Normal Subcutaneous Tissue
Diabetes Clinical Trial 2023: Lipohypertrophy Highlights & Side Effects. Trial Name: NCT02748434 — N/A
Lipohypertrophy 2023 Treatment Timeline for Medical Study. Trial Name: NCT02748434 — N/A
~1 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top